BioSpace News Archive

Clover Biopharmaceuticals, Ltd. today announced that enrollment of the first participants has been completed in a Phase Ⅰ first-in-human study evaluating the company’s RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover’s Trimer-Tag vaccine technology platform.

HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

Zai Lab Limited announced that the 2023 National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include the following medicines and indications.

Dxcover Limited , a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced updates to its executive management team.

Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production.

Aiolos Bio, Inc., today announced the appointments of René van der Merwe, MBChB, as Chief Medical Officer, and Tapan Maniar, Ph.D. as Chief Business Officer.

GSK plc (LSE/NYSE: GSK) today announced the recipients of the inaugural grant program of the COiMMUNITY Initiative, a multipronged effort to support the design of a more systematic, collaborative and equitable approach to helping increase adult immunization rates in the US.

TransCode Therapeutics, Inc. today reported successful completion of a preclinical study comprising four independent replicates with its lead therapeutic candidate, TTX-MC138, in pancreatic adenocarcinoma (PDAC).

NightHawk Biosciences announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing Organization (CDMO), as well as the divestiture of certain non-core assets, in order to focus on the growing sales within its Scorpius BioManufacturing subsidiary (“Scorpius”).

USGI Medical, Inc. (USGI) announced today the United States Food and Drug Administration (FDA) acknowledged the successful completion of a pilot study of its incisionless, endoscopic gastroplasty procedure, known as POSE2.0®, which evaluated weight loss in adults suffering from obesity (body mass index [BMI] 35-40 kg/m²) who have an obesity-related comorbidity, such as diabetes or hypertension.